ArticleFrontiers in genetics2025
Identification of anoikis-related genes to develop a risk model and predict the prognosis and tumor microenvironment in rectal adenocarcinoma.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment and evaluation of a prognostic model for sodium overload necrosis in acute myeloid leukemia.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rectal adenocarcinoma (READ) is a common malignant tumor. This study aims to establish a risk model based on anoikis-related genes (ARGs) to predict prognosis and the tumor microenvironment in READ. Methods: Transcriptomic data and clinical data downloaded from the TCGA and GEO databases were used for differential analysis and Cox regression analysis. An ARGs-based prognostic risk model was constructed for READ. The survival curves and ROC curves were plotted to determine the predictive ability of the model for READ patients. The model was externally validated in the GSE87211 dataset. A nomogram, immune analysis, drug sensitivity analysis, and functional enrichment analysis were also performed to comprehensively validate the model. Results: The risk model included 6 prognostic genes (ALDH1A1, BRCA1, GSN, KRT17, SCD, and SNCG). Kaplan-Meier curves for the TCGA training cohort (P < 0.0001), testing cohort (P = 0.018), and GSE87211 dataset (P = 0.036) showed better prognoses in the low-risk group. The AUC for 1-year, 3-year, and 5-year overall survival in the TCGA training cohort, testing cohort, and GSE87211 dataset were (0.962, 0.923, 0.956), (0.887, 0.838, 0.833), and (0.73, 0.817, 0.743), respectively. The nomogram showed that the risk score served as an independent predictor of overall survival. Drug sensitivity analysis revealed differences in the IC50 values of OSI-027, PLX-4720, UMI-77, and Sapitinib between the high-risk and low-risk groups. Immune microenvironment analysis suggested distinct differences in immune cells between the two risk groups. Enrichment analysis revealed that these prognostic ARGs were primarily enriched in pathways and biological processes related to tumorigenesis. Conclusion: The risk model of ARGs can effectively predict READ prognosis and provide potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.